Like-To The Moon - Tiger Brokers Online Investing Community - To The Moon

7
Comment
Favorite

Dex2021
2022-02-02

Like

AbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi

AbbVie Inc forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster an

AbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

7

Report

Comment

Top
Latest

yatylime
·2022-02-02
ok
Reply
Like
Report
jyip93
·2022-02-02
Like
Reply
Like
Report
kevinlaisq
·2022-02-02
ok
Reply
Like
Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9091160731,"tweetId":"9091160731","gmtCreate":1643806507134,"gmtModify":1676533858209,"author":{"id":3574151786459188,"idStr":"3574151786459188","authorId":3574151786459188,"authorIdStr":"3574151786459188","name":"Dex2021","avatar":"https://static.tigerbbs.com/f65daf6867f2ca5b4ed7835578483879","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9091160731","repostId":2208368622,"repostType":2,"repost":{"id":"2208368622","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1643805900,"share":"https://www.laohu8.com/m/news/2208368622?lang=&edition=full","pubTime":"2022-02-02 20:45","market":"us","language":"en","title":"AbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi","url":"https://stock-news.laohu8.com/highlight/detail?id=2208368622","media":"Dow Jones","summary":"AbbVie Inc    forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster an","content":"<html><head></head><body><p>AbbVie Inc    forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer psoriasis drug Skyrizi beat Wall Street expectations for quarterly sales.</p><p>The company&#39;s best-selling drug Humira is expected to face competition from rivals in the United States in 2023 after it loses exclusivity, and the drugmaker is counting on Botox as well as newer drugs, Skyrizi and Rinvoq, to soften the expected blow to sales.</p><p>Sales of Humira, which is already facing copycat rivals in Europe, rose 3.5% to $5.33 billion in the fourth quarter, missing estimates of $5.41 billion, according to Refinitiv IBES data.</p><p>Total revenue of $14.89 billion also missed estimates of $14.97 billion.</p><p>However, the company reported sales of $895 million for Skyrizi, which beat estimates of $867.22 million, and $626 million in Botox sales for cosmetic uses, which topped estimates of $569.78 million.</p><p>Sales of Rinvoq, which belongs to a class of drugs known JAK inhibitors, jumped 84.4% to $517 million.</p><p>Net earnings rose to $4.04 billion, or $2.26 per share, in the quarter ended Dec. 31, from $36 million, or $0.01 per share, a year ago. The company had recorded a $4.7 billion increase in the contingent consideration liability related to Skyrizi last year.</p><p>Excluding items, AbbVie earned $3.31 per share.</p><p>The company said it expects 2022 adjusted profit to be between $14.00 and $14.20 per share. Analysts were expecting a profit of $13.99 per share.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-02-02 20:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>AbbVie Inc    forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer psoriasis drug Skyrizi beat Wall Street expectations for quarterly sales.</p><p>The company&#39;s best-selling drug Humira is expected to face competition from rivals in the United States in 2023 after it loses exclusivity, and the drugmaker is counting on Botox as well as newer drugs, Skyrizi and Rinvoq, to soften the expected blow to sales.</p><p>Sales of Humira, which is already facing copycat rivals in Europe, rose 3.5% to $5.33 billion in the fourth quarter, missing estimates of $5.41 billion, according to Refinitiv IBES data.</p><p>Total revenue of $14.89 billion also missed estimates of $14.97 billion.</p><p>However, the company reported sales of $895 million for Skyrizi, which beat estimates of $867.22 million, and $626 million in Botox sales for cosmetic uses, which topped estimates of $569.78 million.</p><p>Sales of Rinvoq, which belongs to a class of drugs known JAK inhibitors, jumped 84.4% to $517 million.</p><p>Net earnings rose to $4.04 billion, or $2.26 per share, in the quarter ended Dec. 31, from $36 million, or $0.01 per share, a year ago. The company had recorded a $4.7 billion increase in the contingent consideration liability related to Skyrizi last year.</p><p>Excluding items, AbbVie earned $3.31 per share.</p><p>The company said it expects 2022 adjusted profit to be between $14.00 and $14.20 per share. Analysts were expecting a profit of $13.99 per share.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4534":"瑞士信贷持仓","BK4566":"资本集团","ABBV":"艾伯维公司","BK4559":"巴菲特持仓"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208368622","content_text":"AbbVie Inc    forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer psoriasis drug Skyrizi beat Wall Street expectations for quarterly sales.The company's best-selling drug Humira is expected to face competition from rivals in the United States in 2023 after it loses exclusivity, and the drugmaker is counting on Botox as well as newer drugs, Skyrizi and Rinvoq, to soften the expected blow to sales.Sales of Humira, which is already facing copycat rivals in Europe, rose 3.5% to $5.33 billion in the fourth quarter, missing estimates of $5.41 billion, according to Refinitiv IBES data.Total revenue of $14.89 billion also missed estimates of $14.97 billion.However, the company reported sales of $895 million for Skyrizi, which beat estimates of $867.22 million, and $626 million in Botox sales for cosmetic uses, which topped estimates of $569.78 million.Sales of Rinvoq, which belongs to a class of drugs known JAK inhibitors, jumped 84.4% to $517 million.Net earnings rose to $4.04 billion, or $2.26 per share, in the quarter ended Dec. 31, from $36 million, or $0.01 per share, a year ago. The company had recorded a $4.7 billion increase in the contingent consideration liability related to Skyrizi last year.Excluding items, AbbVie earned $3.31 per share.The company said it expects 2022 adjusted profit to be between $14.00 and $14.20 per share. Analysts were expecting a profit of $13.99 per share.","news_type":1},"isVote":1,"tweetType":1,"viewCount":642,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":100399481,"commentId":"100399481","gmtCreate":1643807208082,"gmtModify":1663243175555,"authorId":4095979609718660,"author":{"id":4095979609718660,"idStr":"4095979609718660","authorId":4095979609718660,"name":"yatylime","avatar":"https://static.tigerbbs.com/25c005852de1ee2dd70fd5e3626e3b66","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9091160731,"objectIdStr":"9091160731","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0},{"id":100399456,"commentId":"100399456","gmtCreate":1643807028281,"gmtModify":1663243174640,"authorId":3568615780432279,"author":{"id":3568615780432279,"idStr":"3568615780432279","authorId":3568615780432279,"name":"jyip93","avatar":"https://static.tigerbbs.com/40bc8cd94658e02bab26b5fb8d25b2da","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9091160731,"objectIdStr":"9091160731","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Like","text":"Like","html":"Like","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0},{"id":100399458,"commentId":"100399458","gmtCreate":1643807052151,"gmtModify":1643807052151,"authorId":3572874548548490,"author":{"id":3572874548548490,"idStr":"3572874548548490","authorId":3572874548548490,"name":"kevinlaisq","avatar":"https://static.tigerbbs.com/329de1199f764a89b7cadf50308e183d","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9091160731,"objectIdStr":"9091160731","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}